When Vijay Sankaran was an MD-PhD student at Harvard Medical School in the mid-2000s, one of his first clinical encounters ...

Esther Nkemakolam runs her fingers through kinetic sand and sings a “Moana” song as UPMC Children’s Hospital nurse Taylor ...

Patients with diagnosis of SCA confirmed by electrophoresis or HPLC and on steady state ... Pattern of hemolysis parameters and association with fetal hemoglobin in sickle cell anemia patients in ...

A groundbreaking new gene therapy for sickle cell patients is now being rolled out for use on the NHS in England, as ITV News' Health Correspondent Rebecca Barry reports A £1.65 million treatment ...

The tests do not differentiate between those with SCD and those with sickle cell trait (SCT). 3 In hemoglobin electrophoresis, an electric current is used to identify and measure the different types ...

A "groundbreaking" £1.65 million treatment has been approved for use on the NHS, offering patients with severe sickle cell disease some hope of a cure. It is believed around 1,700 people could be ...

A sickle cell disease “cure” is to be offered to NHS patients for the first time. The £1.65 million gene therapy called exa-cel, also known under the brand name Casgevy, uses a Nobel Prize ...

Asiawu Imam says the therapy will make a huge difference A gene-editing therapy for sickle cell disease, with a price tag of £1.65m, is to be offered to patients on the NHS in England.

Would the transplant work? What would it look like to have a successful stem cell transplant? Would it be a cure for my sickle cell disease? It was a decision I could think about making because my ...

A gene-editing therapy that offers a “functional cure” for some sickle cell patients has been approved for use on the NHS in England, in a move heralded as a positive “leap” forward. The National ...

Sickle cell trait (SCT), HbAS, represents the carrier state, while other hemoglobin variants include HbCC ... Eligible participants were children aged 3–8 years, confirmed through Hb Electrophoresis ...

Activation of Nrf2, a major transcription factor that drives the antioxidant defense system, is an emerging therapeutic strategy in Sickle Cell Disease (SCD ... Immunoblots were performed using ...